Clinical Trial Update: A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018) [Phase 3]

View source ↗

Summary

A Phase 3 cardiovascular outcomes trial for omarigliptin (MK-3102) in type 2 diabetes mellitus was terminated; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Omarigliptin (omarigliptin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: TERMINATED | Results posted: 2017-12-12